Sell

We recommend a SELL rating on the stock and assign a 16x P/E multiple to its FY25E earnings of Rs 24/share to arrive at a TP of Rs 390/share, implying a downside of 4% from the CMP.

Wipro’s IT Services revenue dipped 2.3% QoQ USD in Q2FY24. The slip was much steeper than our/consensus’ expectations of -0.5%. Revenue growth came in at the lower-end of Wipro’s guidance for Q2FY24.

Given the company's medium-term challenges on demand and uncertain supply-side constraints, we expect Infosys to report sluggish growth in FY24. We recommend investors SELL on the stock until uncertainties settle down.

Strides Pharma (Strides) is streamlining its CDMO business by merging its soft gel capsule business and injectable business of Steriscience with Stelis. It will also rename Stelis to OneSource after completion, and regrouping will help the promoter better align the focus on all the arms of the CDMO business. The combined entity is likely to have revenue of USD 180-200mn in FY25E and management expects to grow 20-25% p.a. thereon.

India Cements (ICEM) is ‘walking-the-talk’ regarding the sale of its non-core assets. In a second such transaction, ICEM has agreed to sell its surplus land in Andhra Pradesh (near Vizag) for INR 700mn to industry-leader UltraTech Cement (UTCEM). In Oct’22, ICEM sold its entire stake in subsidiary Springway Mining Pvt Ltd (SMPL) to JSW Cement for INR 4.77bn.

Glenmark Pharma (GNP) is divesting 75% stake in its API arm Glenmark Lifesciences (GLS) for INR 56.5bn (INR 615 per share) to Nirma Limited valuing GLS at 11.7x FY25E EPS and 6.4x EV/EBITDA. GNP, though, will still hold nearly 7.8% stake in Glenmark Lifesciences. The proceeds from the transaction will be used to pare off debt (INR 43.4bn at the end of FY23) of GNP. We believe the proposed transaction may have a negative impact of 10% on FY25E revenue (of INR 172bn) and EBITDA margin may shrink 150bps, though, repayment of debt may partially offset the impact.